



## Bruce M Wexler

Partner, Litigation Department

brucewexler@paulhastings.com

**Bruce Wexler** is the global co-chair of the Intellectual Property practice at Paul Hastings, overseeing the firm's 100-plus lawyer IP practice. He is also Chair of the Life Sciences Industry Practice Group at Paul Hastings. Mr. Wexler is a trial lawyer with extensive experience litigating high-stakes patent cases in a range of technologies. He has represented clients as lead counsel defending their patents covering multi-million and multi-billion dollar drug products.

Mr. Wexler is also an Adjunct Professor of Law at New York University School of Law, where he teaches an advanced course in "Life Sciences Patent Law."

### AWARDS AND ACCOLADES

- Chambers USA

2017 says Bruce Wexler is "very, very talented and a very bright guy" who is praised by sources for the way in which he "comes up with creative and effective solutions to situations." He represents pharmaceutical companies in high-stakes litigation, where "he not only thinks of the grand design but is also very good tactically."

- The Intellectual Asset Management's IAM Patent 1000 (2017) report refers to him as a "wonderfully gifted lawyer" and "Wexler is phenomenally prepared- there is nobody better at digging into the facts. He is a big picture thinker with excellent presentation skills."

- LMG Life Sciences heralded Mr. Wexler as a "preeminent litigator in the industry" and recognized him as General Patent Litigator of the Year – New York for 2016. His representation of Eli Lilly was also honored by LMG as Hatch-Waxman Impact Case of the Year. He was also a nominee for General Patent Litigator of the Year– New York in 2017.

- The American Lawyer's 2015 Transatlantic Lawyer of the Year – IP

- Winner of 2015 Client Choice Award

- Ranked in Chambers Global 2015, USA, Intellectually Property: Patent

- Chambers USA calls Mr. Wexler a "litigation and trial expert at the firm," noting his ability to "explain complex situations clearly to enable informed decision-

### New York

T: 1(212) 318-6020

F: 1(212) 230-7644

### Practice Areas

Patent Office

Life Sciences and Healthcare

Patent Litigation

Litigation

Intellectual Property

### Admissions

New York Bar

United States Patent &

Trademark Office

### Education

New York University School of Law, J.D. 1992

Rensselaer Polytechnic Institute, B.S. 1989

## Bruce M Wexler (Continued)

making” and his “exceptional writing skills and strong technical ability.”

- In its 2015 IP Stars nationwide analysis, Managing Intellectual Property identified Mr. Wexler as a “fantastic lawyer,” a “standout attorney,” and a “well-respected leader in the field.” Mr. Wexler was named one of the “preeminent litigators in the industry” by LMG Life Sciences Guide and has been a Life Science nominee for Litigator of the Year.
- The Intellectual Asset Management’s IAM Patent 1000 (2012) report refers to him as an “awesomely effective trial lawyer.”
- Ranked in IAM Patent 1000's (2013) survey’s Gold band identifying him as the “crème de la crème” for Litigation by reputation and work on the most high-profile, big-ticket work from the most demanding of clients. According to IAM, Mr. Wexler “takes a robust yet reasonable approach to litigation” and is noted by source as “performing at his best in highly charged contentious scenarios.”
- The Financial Times awarded his successful defense of the Aricept® drug franchise a “standout” notice for innovative lawyering.
- He is recognized in the IAM250 leading New York IP Litigators report as a “really strong substantive lawyer.” He is ranked in The Legal 500 US and featured as a NY “Super Lawyer.” The Legal 500 notes that Mr. Wexler has “extensive patent litigation experience, with strategic considerations and observations being very sophisticated and right to the point” and that he is “splendid at trial.”
- Mr. Wexler is a recipient of the Burton Award for Legal Achievement in writing.

### Recent Representations

- Merck Sharp & Dohme Corp. v. Sandoz Inc. and Accord Healthcare, Inc.

Mr. Wexler served as lead counsel for Merck in patent infringement litigation defending Merck’s patent protecting the active ingredient in Emend® for Injection, an important drug for the prevention of chemotherapy-induced nausea and vomiting. After a six-day bench trial, Judge Sheridan of the District of New Jersey entered judgment in favor of Merck on all aspects of Sandoz’s invalidity defenses, resulting in a complete victory for Merck. In the course of the Court’s 80-page opinion finding in Merck’s favor, the Court noted the lack of credibility of Sandoz’s key expert witness who had been cross-examined by Mr. Wexler.

- Sanofi-Aventis US LLC et al. v. Eli Lilly & Co.

Mr. Wexler served as lead counsel for Eli Lilly & Co. in litigation with Sanofi regarding Eli Lilly’s request to market its insulin glargine drug product Basaglar®. Sanofi brought suit on five patents, relating to a pharmaceutical

---

## Bruce M Wexler (Continued)

composition and injector pen device, listed in the FDA Orange Book for Sanofi's Lantus® and Lantus SoloStar® insulin glargine products. Mr. Wexler successfully led the case through fact and expert discovery, including live-witness Markman proceedings, obtaining important claim construction rulings pertaining to the patents in suit. The case settled on the eve of trial in late 2015 with the press reporting Eli Lilly's ability to launch Basaglar® the following year.

- Eisai Inc. and Eisai Co., Ltd. v. Glenmark Generics, Ltd., Hetero Labs, Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., and Roxane Laboratories, Inc., et al.

Mr. Wexler was lead counsel for Eisai in litigation with five generic defendant groups involving the patents directed to a crystalline form of rufinamide, the active ingredient in Eisai's drug product, Banzel®, an important drug in the treatment of epilepsy. After successfully litigating through fact and expert discovery, Mr. Wexler obtained a victory in Markman proceedings having significant implications for the infringement and validity issues in the case. Mr. Wexler also convinced the Court, during the final pretrial conference, to exclude certain purported testing evidence by the defendants offered in support of their invalidity defense. The case finally settled on favorable terms an hour before opening arguments at trial.

- Merck Sharp & Dohme Corp. v. Apotex Inc.

While district court litigation was ongoing with other generic drug companies, generic drug company Apotex filed a petition for Inter Partes Review (IPR) at the U.S. Patent and Trademark Office seeking to invalidate the patent protecting Merck's Emend® for Injection drug product. Together with Paul Hastings partner Naveen Modi, Mr. Wexler obtained a successful ruling from the PTO rejecting Apotex's invalidity attack and refusing to institute review, and this ruling was subsequently reaffirmed on Apotex's petition for rehearing.

- Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc.

Mr. Wexler was lead counsel for Boehringer Ingelheim in this appeal involving the patent protecting Mirapex®, a key drug in the treatment of Parkinson's disease. Mr. Wexler was hired to handle the appeal after another firm had received an adverse ruling at trial. Mr. Wexler argued and won a complete reversal from the Federal Circuit, with the Court declaring the patent to be valid. The appeal established important precedent concerning the scope of the double patenting safe harbor provision, 35 U.S.C. 121.

- Sandoz Inc. v. Boehringer Ingelheim International GmbH and Boehringer

## Bruce M Wexler (Continued)

Ingelheim Pharmaceuticals, Inc.

Mr. Wexler was lead trial counsel for Boehringer Ingelheim in its counterclaim action for patent infringement against Sandoz. Mr. Wexler argued and won a preliminary injunction ruling, delivered from the bench, preventing Sandoz from launching a generic version of Mirapex®. The court was persuaded to grant the injunction on a patent that had been subject to a license and which would be expiring in several months. The judge deciding this case had, in his immediately preceding patent case, refused both preliminary and permanent injunctive relief in part on the ground that the patentee had previously licensed the patent. Mr. Wexler subsequently negotiated a stipulation continuing the injunction through patent expiration.

- Takeda Pharmaceutical Company Ltd. and Takeda Pharmaceuticals North America Inc. v. Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc.

Mr. Wexler was lead trial counsel for Takeda in two actions enforcing Takeda's patent for its anti-insomnia drug Rozerem® against challenge by generic drug companies Teva and Watson. After two years of litigation through fact and expert discovery, Mr. Wexler obtained a favorable settlement dismissing both companies' patent challenges.

- Eisai Co., Ltd. and Eisai Inc. v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler was lead trial counsel for Eisai in an action defending Eisai's patent protecting Aricept®, the market leading drug for the treatment of Alzheimer's disease, having sales of some \$2 billion/year. Mr. Wexler obtained a preliminary injunction against Teva's threatened launch of a generic version of the drug. Mr. Wexler ensured continued exclusivity of the patent through patent expiration, and successfully defended attempts by Teva to trigger and run out the regulatory exclusivity of a first-filing generic drug applicant.

- Merck & Co., Inc. v. Sandoz Inc.

Mr. Wexler was lead trial counsel for Merck in an action enforcing Merck's patents protecting its oral anti-emetic drug product, Emend®. Mr. Wexler ultimately obtained a consent judgment for his client that included an injunction prohibiting Sandoz from infringement through patent expiration.

- Eisai Co., Ltd. and Eisai Inc. v. Teva Pharmaceuticals USA, Dr. Reddy's Laboratories and Mylan Laboratories

Mr. Wexler was co-lead trial counsel to Eisai in litigation defending Eisai's patent covering Aciphex®, an acid reflux drug with annual US sales in excess

## Bruce M Wexler (Continued)

of \$1 billion. Mr. Wexler and his partner Joe O'Malley initially won summary judgment for Eisai of patent validity. They subsequently succeeded at trial in defeating Teva's and Dr. Reddy's charges of inequitable conduct, and obtained affirmance of that judgment on appeal. The case established helpful precedent for innovator pharmaceutical companies with respect to the standards for judging obviousness of a compound patent.

- Nycomed v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler represented Wyeth (acquired by Pfizer) and Altana Pharma AG (acquired by Nycomed) in a jury trial against three generic pharmaceutical companies regarding the companies' \$2 billion per year ulcer drug Protonix®. The jury upheld the validity of the patent, permitting the plaintiffs to seek recovery of damages caused by an at-risk generic drug launch.

- Apotex Inc. v. Eisai Co., Ltd. and Eisai Inc.

Mr. Wexler was lead counsel for Eisai defending a declaratory judgment action by Apotex alleging that its generic product did not infringe four Eisai patents relating to Aricept®. In August 2010, in a lengthy opinion analyzing the Hatch-Waxman Act legal framework, Mr. Wexler obtained a dismissal of the action, effectively preventing Apotex from triggering and running out a regulatory exclusivity prior to the expiration of Eisai's basic patent covering Aricept®.

- Warner-Lambert Company v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler represented Pfizer (Warner-Lambert Company) during a successful bench trial against Teva involving Pfizer's formulation patent covering its highly successful cardiovascular drug Accupril®. In its decision, the Court found the patent was not invalid for lack of enablement, despite the breadth of the claims. With that trial decision, all issues of infringement, enforceability and validity were decided in Pfizer's favor in the case after eight years of litigation. The case then settled while the appeal of the enablement ruling was pending.

### Speaking Engagements and Publications

- Mr. Wexler's writing has been published in numerous journals, including Forbes, Law360, IP Magazine, Managing IP, and NYU's Journal of Intellectual Property and Entertainment Law.
- He is a regular speaker at legal seminars, including ACI's Paragraph IV Disputes conference.
- Mr. Wexler has been quoted frequently with regard to litigation and practice developments, including in the Wall Street Journal, Bloomberg News, Reuters, The Deal and The New York Times.

## Bruce M Wexler (Continued)

- Mr. Wexler regularly provides his clients with in-house CLE presentations on a variety of topics of interest, and authors client alerts concerning important developments in the law.

### Professional and Community Involvement

- Mr. Wexler advised Congress and key stakeholders during the consideration and enactment of the America Invents Act.
- He is a former judicial law clerk of the U.S. Court of Appeals for the Federal Circuit, where he served under Chief Judge Glenn L. Archer, Jr. He clerked for Chief Judge Archer during the Chief Judge's preparation of influential Federal Circuit decisions including *Markman v. Westview*.

### Education

- New York University School of Law, J.D. (magna cum laude, Order of the Coif)
- Rensselaer Polytechnic Institute, B.S. in Physics (summa cum laude, member - Sigma Pi Sigma honor society)

## News

### May 04, 2020

Paul Hastings' Intellectual Property Practice Shines Bright with 13 Star Litigators in Managing IP's Ranking of IP Stars

### May 01, 2020

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2020

### February 05, 2020

Managing IP Nominates Paul Hastings' IP Practice for Multiple Awards

### January 12, 2020

Paul Hastings IP Practice Ranked in IAM Global Leaders 2020

### October 21, 2019

Merri Moken, Trial Lawyer and IP Strategist, Joins Paul Hastings' Powerhouse Intellectual Property Practice

### October 10, 2019

Paul Hastings Scores Top Rankings in 2019 LMG Life Sciences

### September 19, 2019

## **Bruce M Wexler** (Continued)

Paul Hastings Wins at LMG Life Sciences Awards

**July 26, 2019**

Paul Hastings Nominated for Four LMG Life Sciences Awards

**June 24, 2019**

Paul Hastings Recognized in 2019 Managing Intellectual Property's IP Stars

**June 07, 2019**

Paul Hastings Recognized in 2019 IAM Patent 1000 as One of the Most Sophisticated Patent Litigation Practices

**May 20, 2019**

New York Law Journal Recognizes Paul Hastings Life Sciences IP Litigators as New York Trailblazers

**May 01, 2019**

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2019

**April 08, 2019**

Paul Hastings Wins Top Honors at 2019 Managing IP Americas Awards

**October 11, 2018**

Paul Hastings Scores Top Rankings in LMG Life Sciences for 2018

**September 13, 2018**

Paul Hastings Wins Hatch-Waxman Litigation Firm of the Year at LMG Life Sciences Awards

**June 18, 2018**

Paul Hastings Recognized in 2018 Managing Intellectual Property IP Stars

**June 15, 2018**

Paul Hastings Named Transatlantic IP Team of the Year by The American Lawyer

**June 15, 2018**

Paul Hastings Recognized in 2018 IAM Patent 1000 For Superb Track Record in Patent Litigation

## **Bruce M Wexler** (Continued)

**May 11, 2018**

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2018

**February 05, 2018**

Paul Hastings Wins Law360 Life Sciences Practice Group of the Year

**August 08, 2017**

Paul Hastings Recognized in 2017 IAM Patent 1000 for Pristine Patent Litigation Track Record

**June 05, 2017**

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2017

**February 09, 2017**

Paul Hastings Intellectual Property Practice Continues Leadership in PTAB Filings

**November 30, 2016**

Paul Hastings Scores Top Rankings in LMG Life Sciences for 2016

**October 21, 2016**

Paul Hastings' Litigators Score High Rankings in 2017 Benchmark Litigation

**September 16, 2016**

Paul Hastings Wins Four LMG Life Sciences Awards

**June 14, 2016**

Bruce Wexler Named Transatlantic Lawyer of the Year: Intellectual Property by The American Lawyer

**June 08, 2016**

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2016

**May 20, 2015**

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA 2015

**May 27, 2014**



## **Bruce M Wexler** (Continued)

Paul Hastings Practices and Lawyers Score Top Rankings in Chambers USA  
2014

**March 11, 2014**

Paul Hastings Launches Free Intellectual Property App to Help Decision Makers  
in Pharmaceutical Industry

**June 05, 2013**

Paul Hastings Extensive Practice Strength Highlighted in The Legal 500 United  
States 2013

**May 27, 2013**

Paul Hastings Employment Practice Honored with Chambers "Award for  
Excellence" and Firms Leading Practices and Lawyers Ranked in Chambers  
USA 2013

**June 07, 2012**

Paul Hastings Excels in Chambers USA 2012 Guide

**June 10, 2011**

Paul Hastings Excels in Chambers USA 2011 Guide

**June 14, 2010**

Paul Hastings Garners Top Rankings in Chambers USA 2010 Guide

**June 07, 2010**

Paul Hastings Excels in 2010 Edition of Legal 500 US

**September 10, 2009**

Paul Hastings Secures Dismissal in Patent Infringement Case on Behalf of Eisai

**July 22, 2008**

Patent Litigators Secure Final Victory for Eisai Against Generic Drugmakers

**March 28, 2008**

Paul Hastings Obtains Preliminary Injunction in a Patent Infringement Case on  
Behalf of Eisai

**June 19, 2007**

Paul Hastings Earns Top Marks in the Latest Volume of The Legal 500 US

## **Bruce M Wexler** (Continued)

**May 14, 2007**

Paul Hastings Wins Patent Trial for Eisai Pharmaceuticals

**November 06, 2006**

Paul Hastings Obtains Summary Judgment for Major Pharmaceutical Company

**September 12, 2006**

Paul Hastings Bolsters International IP Practice With Addition of Prominent Patent Litigation Lawyers in New York

## **Insights**

**May 08, 2020**

Bruce Wexler Talks Global IP Updates with Targem Translations

**December 17, 2019**

How to Think About and Successfully Navigate Patent Eligibility After Alice, Myriad, and Mayo

**July 15, 2019**

Key Takeaways for Practitioners from the Athena v. Mayo En Banc Rehearing Petition Denial

**July 03, 2019**

Senate Judiciary Committee Passes Bill Limiting the Number of Patents for BPCIA Litigation

**June 25, 2019**

Senate Hearing on “The State of Patent Eligibility in America”: Analysis of Viewpoints on Looming Section 101 Change

**October 17, 2017**

Five Takeaways from Combination Drug Treatment and Dissolution Range Patent Rulings in Orexigen v. Actavis

**February 07, 2017**

Conversion of Paragraph IV Certification to Paragraph III Did Not Necessarily Deprive Court of Subject Matter Jurisdiction Over Hatch Waxman Act Case

**July 07, 2016**

## Bruce M Wexler (Continued)

Federal Circuit Upholds Patent Eligibility of a Method of Preserving Liver Cells,  
Giving Guidance on Applying Section 101's Exclusion of Natural Laws

**April 26, 2016**

The Gatekeeping Function of Patent Eligibility as Part of a More Complete  
Understanding of § 101 Principles

**March 18, 2016**

Federal Circuit Issues Expansive Ruling in Upholding Jurisdiction over Mylan in  
Delaware

**June 15, 2015**

Federal Circuit Rules Prenatal Diagnostic Patents as Patent Ineligible in *Ariosa*

**August 18, 2014**

Prosecution Bar in Protective Order Does Not Bar Outside Litigation Counsel  
from Participating in an Inter Partes Review Proceeding, SDNY Rules

**July 21, 2014**

Supreme Court Continues to Build Out Its Framework for Patent Eligibility in  
High-Tech and Life Sciences Sectors

**June 19, 2014**

Supreme Court Ruling in *Alice v. CLS Bank* Continues Framework for Patent  
Eligibility Set Forth in *Mayo v. Prometheus*

**April 22, 2014**

Today's Gilead Federal Circuit Decision Is a Significant Change to Double-  
Patenting Law

**March 10, 2014**

Solving Pharma IP Problems, One App at a Time

**February 21, 2013**

New Jersey District Court Holds That a Claim for Infringement Under 35 U.S.C. §  
271(e)(2) May be Stated Without a Paragraph IV Certification

**January 16, 2013**

Supreme Court's Dismissal of Invalidity Counterclaim Based on Covenant Not to  
Sue Raises New Potential Avenues for Argument in Hatch-Waxman Act Cases

## **Bruce M Wexler** (Continued)

**November 16, 2012**

Federal Circuit Ruling Strengthens Defenses Against Enablement Attacks on Drug and Medical Device Patents

**October 08, 2012**

Patent-Eligibility of Isolated DNA: Another Twist in the Prometheus Debate

**October 08, 2012**

Prometheus: A New Dawn for Biotech Patents

**March 29, 2012**

PTO's Proposed Rules for Supplemental Examination Draw Sharp Criticism

**November 21, 2011**

A Sign of Future Biosimilars Litigation?

**September 08, 2011**

Senate Passes Patent Reform Bill Significant Changes to U.S. Patent System to Come

**June 23, 2011**

U.S. House Passes Comprehensive Patent Bill

**May 25, 2011**

Federal Circuit Significantly Tightens Doctrine of Inequitable Conduct Today in Its *En Banc Therasense* Ruling

**April 07, 2011**

Failure to Launch

**March 23, 2011**

Lapsing of Patent for Failure to Pay Maintenance Fees Held Not to Invalidate Terminal Disclaimer

**March 08, 2011**

Full Senate Today Passes Patent Reform (America Invents Act)

**February 03, 2011**

Patent Reform, Including Supplemental Examination, Passes Today's Senate Judiciary Committee Vote

## Bruce M Wexler (Continued)

**December 21, 2010**

Federal Circuits Prometheus Decision Reaffirms Patentability of Methods of Treatment

**November 09, 2010**

Today's En Banc Oral Argument in *Therasense*: The Federal Circuit Wrestles With How Much To Reform Inequitable Conduct

**September 22, 2010**

FDA Revokes Final ANDA Approval, Determining That a Preliminary Injunction Extends the 30 Month Stay

**July 06, 2010**

Will Inequitable Conduct Finally Be Reformed?

**March 19, 2010**

OCA Limitations Imposed by ANDA Filer Provided a Basis for Filing Suit

**March 08, 2010**

New Patent Law Reform Bill Introduced in the Senate

**January 27, 2010**

Patent Owner Protected by Safe Harbor Provision

**March 04, 2009**

Patent Law Reform Bills Introduced in Congress

**January 07, 2009**

New District of New Jersey Local Patent Rules Require Early Action in Pharmaceutical Patent Cases

**August 21, 2007**

Federal Circuit Overrules Precedent - A Sea Change in the Law on Willfulness

## Rankings & Awards

**May 01, 2020**

Recognized by Chambers USA 2020

**May 01, 2020**

## **Bruce M Wexler** (Continued)

Ranked among Managing IP's 2020 IP Stars

### **September 30, 2019**

Recognized as LMG Life Sciences Stars for 2019

### **June 07, 2019**

Recognized by IAM Patent 1000 for 2019

### **April 26, 2019**

Recognized by Chambers USA 2019

### **April 05, 2019**

Recognized by Managing IP as the Life Sciences IP Litigation Firm of the Year

### **February 14, 2019**

Recognized by Chambers Global 2019

### **January 30, 2019**

Recognized as the 2019 Post-Grant Firm of the Year by IAM Magazine

### **October 12, 2018**

Recognized as LMG Life Sciences Stars for 2018

### **September 13, 2018**

Recognized as the Hatch-Waxman Litigation Firm of the Year by LMG Life Sciences

### **June 15, 2018**

Recognized as the Transatlantic IP Team of the Year by The American Lawyer

### **June 15, 2018**

Recognized by IAM Patent 1000 for 2018

### **May 15, 2018**

Recognized by Chambers USA 2018

### **February 01, 2018**

Recognized as Law360 Practice Group of the Year in Life Sciences

### **October 06, 2017**

Recognized as LMG Life Sciences Stars for 2017

## **Bruce M Wexler** (Continued)

**June 06, 2017**

Recognized by IAM Patent 1000 for 2017

**June 05, 2017**

Recognized by Chambers USA 2017

**November 30, 2016**

Recognized as LMG Life Sciences Stars for 2016

**October 21, 2016**

Benchmark Litigation 2017

**September 16, 2016**

Recognized at the 2016 LMG Life Sciences Awards

**July 27, 2016**

Shortlisted for four LMG Life Sciences Awards for 2016

**June 10, 2016**

The American Lawyer's Transatlantic Lawyer of the Year: Intellectual Property

**June 08, 2016**

Recognized by Chambers USA 2016

**May 27, 2016**

Recognized by IAM Patent 1000 for 2016

**December 09, 2015**

Benchmark Litigation 2016

**June 17, 2015**

Recognized by IAM Patent 1000 for 2015

**May 15, 2015**

Managing IP's 2015 IP Stars

**October 09, 2014**

Recognized by LMG Life Sciences for Life Sciences IP Litigation

**June 05, 2014**

Recognized by IAM Patent 1000 for 2014

## **Bruce M Wexler** (Continued)

**April 29, 2014**

Managing IP's 2014 Intellectual Property Stars

**August 12, 2013**

Legal Media Group's 2013 LMG Life Science Awards

**August 12, 2013**

Legal Media Group's 2013 LMG Life Science Awards

**June 12, 2012**

Recognized by IAM Patent 1000 for 2012

**May 01, 2011**

Intellectual Asset Management

**December 06, 2010**

Financial Times

**November 30, 2010**

Intellectual Property Magazine